(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌
![(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 结构式](https://img.chemicalbook.com/CAS/20180808/GIF/290304-24-4.gif)
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 性质
| 沸点 | 1128.4±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.67±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 不溶于水；不溶于乙醇；超声波检测下 DMSO 中≥17.92 mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 7.39±0.60(Predicted) |
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 用途与合成方法
|
Topoisomerase
|
Daunorubicins/Doxorubicins
|
Daun02 is a prodrug, which is converted by β-galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca 2+ )-dependent action potentials in neuroblastoma cells. Daunorubicin is a topoisomerase inhibitor. Daun02 is a good substrate for β-galactosidase (β-gal). The concentration of Daun02 producing 50% (EC 50 ) decrease in cell viability is 0.5 μM, 1.5 μM, and 3.5 μM for T47-D, Panc02, and MCF-7, respectively.
Daun02 is a good substrate for β-gal with K m and V max values of 0.37 mM and 8.6 μmol/min/mg protein. At a concentration of 10 -5 M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin.
(8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-13061 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 | 290304-24-4 | 2mg | 1800 |
| 2024-01-25 | HY-13061 | (8S,10S)-8-乙酰基-7,8,9,10-四氢-6,8,11-三羟基-1-甲氧基-10-[[2,3,6-三脱氧-3-[[[[4-(BETA-D-吡喃半乳糖基氧基)-3-硝基苯基]甲氧基]羰基]氨基]-ALPHA-L-来苏-己糖吡喃糖苷]氧基]-5,12-并四苯醌 | 290304-24-4 | 5mg | 2800 |
